Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study
PurposePatients with recurrent or metastatic cervical cancer (R/M CC) who progress after immunotherapy face limited treatment options. This study aimed to explore whether cadonilimab, a novel bispecific antibody targeting programmed cell death protein …